JPS58148822A - コレカルシフエロ−ル誘導体を含む薬剤 - Google Patents

コレカルシフエロ−ル誘導体を含む薬剤

Info

Publication number
JPS58148822A
JPS58148822A JP58019894A JP1989483A JPS58148822A JP S58148822 A JPS58148822 A JP S58148822A JP 58019894 A JP58019894 A JP 58019894A JP 1989483 A JP1989483 A JP 1989483A JP S58148822 A JPS58148822 A JP S58148822A
Authority
JP
Japan
Prior art keywords
epimer
treatment
disease state
epimers
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP58019894A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0474332B2 (2
Inventor
アルフレツド・ボリス
ジヨン・ジヨセフ・パ−トリツジ
ミラン・ラドジエ・ウスココビツク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JPS58148822A publication Critical patent/JPS58148822A/ja
Publication of JPH0474332B2 publication Critical patent/JPH0474332B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP58019894A 1982-02-12 1983-02-10 コレカルシフエロ−ル誘導体を含む薬剤 Granted JPS58148822A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34838982A 1982-02-12 1982-02-12
US348389 1982-02-12

Publications (2)

Publication Number Publication Date
JPS58148822A true JPS58148822A (ja) 1983-09-05
JPH0474332B2 JPH0474332B2 (2) 1992-11-26

Family

ID=23367827

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58019894A Granted JPS58148822A (ja) 1982-02-12 1983-02-10 コレカルシフエロ−ル誘導体を含む薬剤

Country Status (12)

Country Link
EP (1) EP0086476B1 (2)
JP (1) JPS58148822A (2)
AU (1) AU560066B2 (2)
BE (1) BE895884A (2)
CA (1) CA1206882A (2)
DE (2) DE3304819A1 (2)
IE (1) IE54722B1 (2)
IL (1) IL67881A0 (2)
IT (1) IT1173654B (2)
NZ (1) NZ203251A (2)
PH (1) PH17993A (2)
ZA (1) ZA83923B (2)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
EP0154185B1 (en) * 1984-02-08 1988-10-05 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Calciferol derivatives
JPS6391323A (ja) * 1986-10-03 1988-04-22 Kureha Chem Ind Co Ltd 抗尿路結石症剤
DE3765250D1 (de) * 1987-10-30 1990-10-31 Kureha Chemical Ind Co Ltd Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.
JP2856444B2 (ja) * 1989-07-28 1999-02-10 呉羽化学工業株式会社 ビタミンｄ▲下３▼代謝産物製剤
GB202016614D0 (en) 2020-10-20 2020-12-02 King S College London Compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH644100A5 (de) * 1979-09-14 1984-07-13 Hoffmann La Roche Cholecalciferolderivate.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCH.BIOCHEM.BIOPHYS=1981 *
BIOCHEMISTY=1981 *

Also Published As

Publication number Publication date
DE3304819A1 (de) 1983-08-25
EP0086476B1 (de) 1986-05-07
ZA83923B (en) 1983-11-30
PH17993A (en) 1985-02-28
CA1206882A (en) 1986-07-02
AU1134083A (en) 1983-08-18
JPH0474332B2 (2) 1992-11-26
IE830285L (en) 1983-08-12
EP0086476A3 (en) 1983-11-09
IE54722B1 (en) 1990-01-17
IT1173654B (it) 1987-06-24
DE3363334D1 (en) 1986-06-12
IL67881A0 (en) 1983-06-15
BE895884A (fr) 1983-08-11
EP0086476A2 (de) 1983-08-24
AU560066B2 (en) 1987-03-26
NZ203251A (en) 1986-04-11
IT8319545A0 (it) 1983-02-11

Similar Documents

Publication Publication Date Title
EP0557065B1 (en) Spheroid formulation
PT2321273E (pt) Administração semanal de 25-hidroxi-vitamina d3 para manter concentração sanguínea elevada numa farmacocinética de estado estacionário
DE3346525C2 (de) Pharmazeutische Zubereitung mit speziellen 1,2-Diacyl-glycero-3-phosphocholinen zur Behandlung von Erkrankungen im Magen-Darmbereich
EP3434268A1 (en) Compounds for the treatment of obesity and methods of use thereof
CN104394871A (zh) 2-亚甲基-19-去甲-(20S)-1α,25-二羟基维生素D3治疗继发性甲状旁腺功能亢进的用途
ES2586930T3 (es) Composición para el tratamiento de la esterilidad
JPS58148822A (ja) コレカルシフエロ−ル誘導体を含む薬剤
US4252797A (en) Corticosteroid calcium compositions and treatment of rheumatic diseases therewith
Gutierrez et al. Mitotane (o, p′-DDD)
EP0127297B1 (en) Vitamin composition with enhanced bioavailability and method of administering same
DE10101522A1 (de) Synergistische Zusammensetzung die Ascorbat und Lysin für Zustände enthält, zur Behandlung extrazellularer Matrixdegeneration
JPS5940137B2 (ja) 経口投与用医薬組成物
HU206261B (en) Process for producing pharmaceutical compositions suitable for treating pulmonary hypertension caused by neutralization by heparin protemin, and comprising 7-oxabicyclo/2.2.1/-5-heptanoic acid derivative as active ingredient
CN105250316A (zh) 一种含二联苯酚的抗癫痫药物组合
JPS58208231A (ja) コレカルシフエロ−ル誘導体含有薬剤
EP1465642B1 (fr) Protection de la neuritoxicite de l'oxaliplatine par administration de calcium et de magnesium
JPH08208464A (ja) 高脂血症の治療及び予防薬
JPS5938204B2 (ja) 再生不良性貧血治療剤
JPH0443887B2 (2)
CH694549A5 (de) Verwendung einer synergistischen Zusammensetzung, die Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeration.
SK68597A3 (en) Kit for osteoporosis treatment cycle
IE55230B1 (en) Use of a cholecalciferol derivative
Vangelista et al. Effects of defibrotide in acute renal failure due to thrombotic microangiopathy
RU2084181C1 (ru) Способ получения биологически активной прополисной пищевой добавки
US3551570A (en) Composition and method for treating inflammation with oxyphenbutazone and indomethacin